Cannasat changes name to Cynapsus Therapeutics
Cannasat Therapeutics Inc. announced that it received shareholder approval to change its corporate name to Cynapsus Therapeutics Inc.. The approval was granted at the Annual General Shareholder Meeting held in Toronto. The Company's stock symbol will remain as "CTH" on the TSX Venture Exchange.
"Since my appointment as President and CEO late last year, my mandate has been to build significant value through the in-licensing of a lower risk Parkinson's Disease project while advancing our existing cannabinoid program," said Anthony Giovinazzo, President and CEO. "As I communicated to shareholders in February, 2010, a key part of my plan is to refocus the Company from a narrow concentration on cannabinoid drug candidates, to a more diversified emphasis on CNS (Central Nervous System) candidates. I believe the name Cynapsus, which is drawn loosely from the word "synapse", more accurately reflects the company's new focus and direction, and I look forward to reporting further progress and developments in the months ahead."
The company has a new logo and corporate identity and will be updating its web site to keep its investors and partners up to date on the progress of its drug development programs.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
